- Home
- MDLZ vs VRTX Comparison
MDLZ vs VRTX Comparison
Compare MDLZ & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDLZ
- VRTX
- Stock Information
- Founded
- MDLZ 2000
- VRTX 1989
- Country
- MDLZ United States
- VRTX United States
- Employees
- MDLZ N/A
- VRTX N/A
- Industry
- MDLZ Packaged Foods
- VRTX EDP Services
- Sector
- MDLZ Consumer Staples
- VRTX Technology
- Exchange
- MDLZ Nasdaq
- VRTX Nasdaq
- Market Cap
- MDLZ 82.0B
- VRTX 96.6B
- IPO Year
- MDLZ N/A
- VRTX 1991
- Fundamental
- Price
- MDLZ $62.67
- VRTX $403.30
- Analyst Decision
- MDLZ Buy
- VRTX Buy
- Analyst Count
- MDLZ 19
- VRTX 25
- Target Price
- MDLZ $71.68
- VRTX $493.64
- AVG Volume (30 Days)
- MDLZ 7.2M
- VRTX 1.7M
- Earning Date
- MDLZ 10-28-2025
- VRTX 11-03-2025
- Dividend Yield
- MDLZ 3.19%
- VRTX N/A
- EPS Growth
- MDLZ N/A
- VRTX N/A
- EPS
- MDLZ 2.75
- VRTX 14.07
- Revenue
- MDLZ $37,105,000,000.00
- VRTX $11,418,800,000.00
- Revenue This Year
- MDLZ $7.91
- VRTX $10.90
- Revenue Next Year
- MDLZ $4.57
- VRTX $9.57
- P/E Ratio
- MDLZ $22.79
- VRTX $28.67
- Revenue Growth
- MDLZ 3.14
- VRTX 10.46
- 52 Week Low
- MDLZ $53.95
- VRTX $362.50
- 52 Week High
- MDLZ $72.70
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- MDLZ 48.98
- VRTX 56.27
- Support Level
- MDLZ $61.22
- VRTX $374.17
- Resistance Level
- MDLZ $63.33
- VRTX $399.10
- Average True Range (ATR)
- MDLZ 1.27
- VRTX 9.07
- MACD
- MDLZ -0.02
- VRTX 3.43
- Stochastic Oscillator
- MDLZ 38.87
- VRTX 77.19
About MDLZ Mondelez International Inc.
Mondelez has operated independently since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack enclave with a presence in the biscuit (49% of sales as of the end of fiscal 2024), chocolate (31%), gum/candy (11%), beverage (3%), and cheese and grocery (6%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, and Cadbury. The firm derives around one-third of its revenue from developing markets, just more than one-third from Europe, and the remainder from North America.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.